ArticleClinical and translational medicine2026

Correction to "Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S-1 for neoadjuvant therapy of locally advanced gastric cancer with HER2-overexpressing: Preliminary results of a prospective, single-arm, phase II study".

PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.